National Cancer Institute

Bevacizumab prolongs life in ongoing trial of cervical cancer

Bevacizumab plus chemotherapy improved survival in women with advanced, recurrent, or persistent cervical cancer, according to interim findings.

All PARP inhibitors not created equal in terms of PARP-trapping power

Research findings indicate that PARP inhibitors vary from one another in their ability to trap PARP proteins.

Cloud data on cancer may lead to more effective treatments


Cloud technology is now being used to collect detailed information from thousands of cancer samples with the goal of helping doctors make better predictions about how a patient's illness will progress and what type of treatment will be most effective.

Special ultrasound device approved for dense breasts

The somo-V Automated Breast Ultrasound System received FDA approval for use in combination with standard mammography in women with dense breast tissue.

Disparities in surgical management of thyroid cancer


ATA guidelines for well-differentiated thyroid cancer recommend therapeutic neck dissection when the disease is clinically involved or metastatic and prophylactic central neck dissection when tumors are advanced. Nonetheless, though these established guidelines are in place, the surgical management of cervical nodes varies greatly.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs